U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H17N3S.2ClH.H2O
Molecular Weight 302.264
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIPEXOLE DIHYDROCHLORIDE

SMILES

O.Cl.Cl.CCCN[C@H]1CCC2=C(C1)SC(N)=N2

InChI

InChIKey=APVQOOKHDZVJEX-QTPLPEIMSA-N
InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula C10H17N3S
Molecular Weight 211.327
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf

Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Pramipexole is used for the treatment of signs and symptoms of idiopathic Parkinson's disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [EC50]
27.0 nM [EC50]
15.0 nM [EC50]
4.81 µM [IC50]
5.37 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Primary
MIRAPEX

Approved Use

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.268 ng/mL
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.29 ng × h/mL
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
0.375 mg single, oral
dose: 0.375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRAMIPEXOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
Disc. AE: Hallucination, Hypotension...
AEs leading to
discontinuation/dose reduction:
Hallucination (1.3%)
Hypotension (0.5%)
Peripheral edema (0.5%)
Sources:
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
Disc. AE: Hallucinations, Sleepiness...
AEs leading to
discontinuation/dose reduction:
Hallucinations (4.3%)
Sleepiness (3%)
Dizziness (2.5%)
Memory loss (1.2%)
Paranoia (0.6%)
Sources:
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
DLT: Drowsiness, Muscle spasms...
Dose limiting toxicities:
Drowsiness (3.6%)
Muscle spasms (1.8%)
Insomnia (1.8%)
Vertigo (1.8%)
Ankle swelling (1.8%)
Hallucination (3.6%)
Nausea (1.8%)
Sources:
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Disc. AE: Hallucination, Peripheral edema...
AEs leading to
discontinuation/dose reduction:
Hallucination (1%)
Peripheral edema (0.8%)
Abdominal pain upper (0.6%)
Myocardial infarction (0.6%)
Nausea (0.6%)
Pneumonia (0.6%)
Vomiting (0.6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
Peripheral edema 0.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
Hallucination 1.3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 61.6
Health Status: unhealthy
Age Group: 61.6
Sex: M+F
Sources:
Paranoia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
Memory loss 1.2%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
Dizziness 2.5%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
Sleepiness 3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
Hallucinations 4.3%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 62.7
Health Status: unhealthy
Age Group: 62.7
Sex: M+F
Sources:
Ankle swelling 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Insomnia 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Muscle spasms 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Nausea 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Vertigo 1.8%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Drowsiness 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Hallucination 3.6%
DLT
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, 62.8
Health Status: unhealthy
Age Group: 62.8
Sex: M+F
Sources:
Abdominal pain upper 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Myocardial infarction 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Nausea 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Pneumonia 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Vomiting 0.6%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Peripheral edema 0.8%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Hallucination 1%
Disc. AE
1.5 mg 3 times / day multiple, oral
Recommended
Dose: 1.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1.5 mg, 3 times / day
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
2001 Nov-Dec
Daytime sleepiness and other sleep disorders in Parkinson's disease.
2001 Oct 23
Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists.
2001 Sep-Oct
Restless legs syndrome in the older adult: diagnosis and management.
2002
Sleep disorders in Parkinson's disease: epidemiology and management.
2002
Choosing the right dopamine agonist for patients with Parkinson's disease.
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
2002 Apr 3
[Pramipexole in Parkinson disease. Results of a treatment observation].
2002 Aug
Two advances in the management of Parkinson disease.
2002 Aug
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
2002 Dec 24
[Rapid-eye-movement sleep disorders in Parkinson's disease].
2002 Feb
Restless legs syndrome: treatment with dopaminergic agents.
2002 Feb 26
Long-term studies of dopamine agonists.
2002 Feb 26
Neuroprotection and dopamine agonists.
2002 Feb 26
[Rhabdomyolysis as a complication of Parkinson's disease].
2002 Jan-Feb
Pergolide in the treatment of patients with early and advanced Parkinson's disease.
2002 Jan-Feb
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
2002 Jun
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
2002 May 14
Restless legs syndrome augmentation and pramipexole treatment.
2002 Nov
Do dopamine agonists or levodopa modify Parkinson's disease progression?
2002 Nov
Dopamine agonists and neuroprotection in Parkinson's disease.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Neuroprotection in idiopathic Parkinson's disease.
2002 Oct
Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
2002 Oct
Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
2002 Oct-Dec
Review: selegiline improves symptoms and levodopa is better than pramipexole for motor function in untreated Parkinson disease.
2002 Sep-Oct
Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.
2003
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
2003
Dopamine agonists induce episodes of irresistible daytime sleepiness.
2003
Current status of Parkinson's disease treatment in Korea.
2003 Aug
Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.
2003 Aug 15
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
2003 Aug 8
Loss of color vision during long-term treatment with pramipexole.
2003 Jan
Sleepwalking and sleep terrors in prepubertal children: what triggers them?
2003 Jan
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
2003 Jul
Parkinson's disease: is the initial treatment established?
2003 Jul
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
2003 Jul
Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment.
2003 Jun
[Treatment of restless legs syndrome in uremic patients undergoing dialysis with pramipexole: preliminary results].
2003 Jun
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003 May
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
2003 Nov
Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor.
2003 Nov 21
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
2003 Oct
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.
2003 Oct
Current treatment options for restless legs syndrome.
2003 Oct
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
2003 Oct 8
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
2003 Sep
Clinical strategies to prevent and delay motor complications.
2003 Sep 23
Patents

Sample Use Guides

Dosages should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.
Route of Administration: Oral
Pramipexole suppressed H2O2-induced ARPE-19 cell death in vitro at concentrations of 10(-6) M or higher.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:18 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:18 GMT 2025
Record UNII
3D867NP06J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
EMA EPAR   EP   MI   USP-RS   WHO-DD  
Preferred Name English
PRAMIPEXOLE DIHYDROCHLORIDE
ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
SND-919CL2Y
Code English
SND919CL2Y
Code English
SIFROL
Brand Name English
PRAMIPEXOLE HYDROCHLORIDE MONOHYDRATE
Common Name English
PRAMIPEXOLE TEVA
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [EMA EPAR]
Common Name English
PNU-98528E
Code English
PRAMIPEXOLE DIHYDROCHLORIDE [USP MONOGRAPH]
Common Name English
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate
Systematic Name English
MIRAPEX
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE [VANDF]
Common Name English
PRAMIPEXOLE ACCORD
Brand Name English
MIRAPEXIN
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [USP-RS]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE HYDRATE [JAN]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE [USAN]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE [MART.]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [EP MONOGRAPH]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE HYDRATE
JAN  
Common Name English
OPRYMEA
Brand Name English
Pramipexole dihydrochloride monohydrate [WHO-DD]
Common Name English
PRAMIPEXOLE DIHYDROCHLORIDE [ORANGE BOOK]
Common Name English
PRAMIPEXOLE HYDROCHLORIDE
MART.  
Common Name English
DAQUIRAN
Brand Name English
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS PRAMIPEXOLE ACCORD (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS MIRAPEXIN (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS PRAMIPEXOLE TEVA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS SIFROL (AUTHORIZED: RESTLESS LEGS SYNDROME)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS MIRAPEXIN (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS PRAMIPEXOLE ACCORD (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
NCI_THESAURUS C66884
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS OPRYMEA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS DAQUIRAN (WITHDRAWN: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
EMA ASSESSMENT REPORTS SIFROL (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
NCI_THESAURUS C38149
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID1044227
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
RS_ITEM_NUM
1553859
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
RXCUI
236747
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY RxNorm
CAS
191217-81-9
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
DAILYMED
3D867NP06J
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
ChEMBL
CHEMBL301265
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
CHEBI
51147
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
CHEBI
51148
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
DRUG BANK
DBSALT001198
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
EVMPD
SUB25197
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
NCI_THESAURUS
C29374
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
SMS_ID
100000091470
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
USAN
KK-01
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
EVMPD
SUB12563MIG
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
PUBCHEM
166589
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
FDA UNII
3D867NP06J
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
MERCK INDEX
m9095
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY Merck Index
EVMPD
SUB04004MIG
Created by admin on Mon Mar 31 17:59:18 GMT 2025 , Edited by admin on Mon Mar 31 17:59:18 GMT 2025
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY